Literature DB >> 3885958

Evaluation of D-penicillamine in juvenile chronic arthritis. A double-blind, multicenter study.

A M Prieur, C Piussan, P Manigne, P Bordigoni, C Griscelli.   

Abstract

Seventy-four children with juvenile chronic arthritis were entered into a 6-month, multicenter, comparative double-blind study of the efficacy of D-penicillamine versus placebo. The results were evaluated in 70 patients, 55 of whom completed 6 months of the study. Improvement was observed in the total number of stiff joints, total number of painful joints, and total severity index measuring joint pain. There was also a significant reduction in the concurrent use of nonsteroidal anti-inflammatory drugs. D-penicillamine was well-tolerated in all but 2 patients. Some children in the placebo group exhibited definite improvement; however, relapses that were observed were mainly in that group. These results confirm the efficacy of D-penicillamine for the treatment of joint involvement in juvenile chronic arthritis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3885958     DOI: 10.1002/art.1780280404

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

Review 1.  Management of rheumatic diseases in children.

Authors:  B H Athreya
Journal:  Indian J Pediatr       Date:  1996 May-Jun       Impact factor: 1.967

Review 2.  Medical management of children with juvenile rheumatoid arthritis.

Authors:  J T Cassidy
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

3.  Methotrexate therapy in systemic-onset juvenile rheumatoid arthritis in Saudi Arabia: a retrospective analysis.

Authors:  W al-Sewairy; A al-Mazyed; S al-Balaa; S Bahabri
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

4.  Current management of juvenile arthritis.

Authors:  J Chaitow
Journal:  Indian J Pediatr       Date:  1986 Sep-Oct       Impact factor: 1.967

5.  D-penicillamine in rheumatoid arthritis.

Authors:  P Junker
Journal:  Indian J Pediatr       Date:  1986 Sep-Oct       Impact factor: 1.967

Review 6.  Juvenile rheumatoid arthritis: therapeutic perspectives.

Authors:  Ian C Chikanza
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 7.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

Review 8.  A risk-benefit assessment of slow-acting antirheumatic drugs in rheumatoid arthritis.

Authors:  A A Kalla; A F Tooke; E Bhettay; O L Meyers
Journal:  Drug Saf       Date:  1994-07       Impact factor: 5.606

Review 9.  Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis.

Authors:  Alex R Kemper; Heather A Van Mater; Remy R Coeytaux; John W Williams; Gillian D Sanders
Journal:  BMC Pediatr       Date:  2012-03-15       Impact factor: 2.125

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.